Amy Jo Chien, MD
Hematology/Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 2
- Since medical school
- 23 years
- Harvard Medical School, 2003
Offices
2 locations · University of California San Francisco · UCSF Medical Group Business Services
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chien’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A95906 · Current
Licensed to practise in California · since 2006 · expires 2027-12-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$81,445
Medicare paid this office $81,445 for 135 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 97 | $26,178 | $123 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 87 | $2,705 | $15 |
| New patient visit (60+ min) | 17 | $2,681 | $158 |
| Return visit (30+ min) | 14 | $1,566 | $87 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 17 | $1,198 | $28 |
See all 6 services
| Long return visit (40+ min) | 97 | $26,178 | $123 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 87 | $2,705 | $15 |
| New patient visit (60+ min) | 17 | $2,681 | $158 |
| Return visit (30+ min) | 14 | $1,566 | $87 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 17 | $1,198 | $28 |
| Short return visit (20+ min) | 17 | $957 | $53 |
Who their Medicare patients are
135 Original Medicare patients in 2024. Average age 70 · Women 87% · Also on Medicaid 18% · Health risk score 1.91. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: Cancer 75% · High blood pressure 50% · Depression 27% · Coronary heart disease 15% · Chronic kidney disease 15% · Diabetes 13% · Atrial fibrillation 13% · Heart failure 10%.
The office billed $803,229, Medicare allowed $103,343 and paid $81,445; for 1,631 services of 31 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 135 | 1,631 | 70 | 1.91 | $803,229 | $81,445 |
| 2023 | 132 | 943 | 71 | 1.88 | $542,715 | $59,119 |
| 2022 | 133 | 966 | 71 | 1.75 | $449,286 | $48,486 |
| 2021 | 155 | 304 | 70 | 2.03 | $210,575 | $32,907 |
| 2020 | 118 | 254 | 70 | 1.87 | $187,531 | $23,901 |
| 2019 | 92 | 216 | 70 | 1.98 | $169,497 | $20,586 |
| 2018 | 89 | 176 | 69 | 1.65 | $129,354 | $16,307 |
| 2017 | 74 | 198 | 71 | 1.50 | $132,246 | $17,570 |
| 2016 | 94 | 214 | 71 | 1.51 | $138,550 | $18,061 |
| 2015 | 96 | 270 | 72 | 1.55 | $158,366 | $21,918 |
| 2014 | 69 | 187 | 72 | 1.27 | $104,000 | $14,200 |
| 2013 | 67 | 147 | 70 | 1.35 | $79,592 | $11,568 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 116 | $29,289 | $122 |
| New patient visit (60+ min) | 13 | $1,987 | $153 |
| Short return visit (20+ min) | 12 | $988 | $58 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $563 | $28 |
2022: 2 services
| Long return visit (40+ min) | 93 | $24,721 | $121 |
| New patient visit (60+ min) | 24 | $3,587 | $149 |
2021: 4 services
| Long return visit (40+ min) | 97 | $24,824 | $124 |
| New patient visit (60+ min) | 19 | $3,024 | $159 |
| Return visit (30+ min) | 26 | $2,271 | $84 |
| Short return visit (20+ min) | 25 | $1,501 | $52 |
2020: 4 services
| Long return visit (40+ min) | 70 | $17,311 | $97 |
| New patient visit (60+ min) | 19 | $2,873 | $151 |
| Return visit (30+ min) | 32 | $2,443 | $72 |
| Short return visit (20+ min) | 14 | $651 | $46 |
2019: 2 services
| Long return visit (40+ min) | 76 | $16,207 | $93 |
| New patient visit (60+ min) | 23 | $3,027 | $132 |
2018: 3 services
| Long return visit (40+ min) | 60 | $11,300 | $90 |
| New patient visit (60+ min) | 22 | $3,278 | $149 |
| Return visit (30+ min) | 17 | $1,291 | $59 |
2017: 3 services
| Long return visit (40+ min) | 53 | $12,032 | $90 |
| New patient visit (60+ min) | 18 | $2,701 | $150 |
| Return visit (30+ min) | 25 | $2,463 | $67 |
2016: 2 services
| Long return visit (40+ min) | 54 | $12,181 | $91 |
| Return visit (30+ min) | 39 | $3,643 | $61 |
2015: 4 services
| Long return visit (40+ min) | 34 | $8,388 | $94 |
| Return visit (30+ min) | 57 | $7,061 | $67 |
| New patient visit (60+ min) | 20 | $3,015 | $151 |
| Short return visit (20+ min) | 23 | $1,053 | $41 |
2014: 3 services
| Long return visit (40+ min) | 21 | $7,069 | $96 |
| Return visit (30+ min) | 40 | $3,707 | $66 |
| Short return visit (20+ min) | 31 | $1,600 | $44 |
2013: 3 services
| Long return visit (40+ min) | 45 | $7,573 | $93 |
| Return visit (30+ min) | 24 | $2,005 | $63 |
| Short return visit (20+ min) | 13 | $575 | $38 |
Medicaid work
$9,142 in 2024
Medicaid paid $9,142 for 60 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 60 | $9,142 |
| 2024 | 60 | 1 | 18 | $9,142 |
| 2023 | 79 | 1 | 17 | $9,532 |
| 2022 | 94 | 1 | 15 | $10,859 |
| 2021 | 135 | 1 | 19 | $17,185 |
| 2020 | 54 | 1 | 16 | $6,876 |
| 2019 | 57 | 1 | 14 | $5,020 |
| 2018 | 162 | 1 | 16 | $12,861 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 79 | $9,532 |
2022
| Long return visit (40+ min) | 94 | $10,859 |
2021
| Long return visit (40+ min) | 135 | $17,185 |
2020
| Long return visit (40+ min) | 54 | $6,876 |
2019
| Long return visit (40+ min) | 57 | $5,020 |
2018
| Long return visit (40+ min) | 162 | $12,861 |
Drugs they prescribed that Part D paid
$482,165
Pharmacies billed $482,165 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
141 generic and 37 brand-name prescriptions · $482,165 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Kisqali | 24 | $368,147 | $15,339 |
| Letrozole | 87 | $3,429 | $39 |
| Anastrozole | 25 | $545 | $22 |
Year by year
| 2024 | 178 | 58 | None | 21% | $482,165 |
| 2023 | 209 | 61 | None | 16% | $274,801 |
| 2022 | 234 | 61 | None | None | $374,885 |
| 2021 | 232 | 60 | None | 17% | $382,362 |
| 2020 | 335 | 67 | None | 12% | $209,307 |
| 2019 | 348 | 71 | None | 11% | $108,184 |
| 2018 | 391 | 91 | 7% (29) | 4% | $37,135 |
| 2017 | 362 | 54 | None | 8% | $207,581 |
| 2016 | 375 | 57 | None | 12% | $301,489 |
| 2015 | 319 | 54 | None | 16% | $233,828 |
| 2014 | 227 | 42 | None | 9% | $20,307 |
| 2013 | 224 | 44 | None | None | $17,479 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Letrozole | 118 | $8,537 | $72 |
| Anastrozole | 22 | $602 | $27 |
2022: 3 drugs
| Ibrance | 17 | $232,939 | $13,702 |
| Letrozole | 118 | $6,742 | $57 |
| Anastrozole | 36 | $731 | $20 |
2021: 3 drugs
| Ibrance | 23 | $288,197 | $12,530 |
| Letrozole | 116 | $4,761 | $41 |
| Anastrozole | 23 | $514 | $22 |
2020: 6 drugs
| Letrozole | 110 | $3,947 | $36 |
| Anastrozole | 34 | $837 | $25 |
| Ondansetron | 18 | $408 | $23 |
| Prochlorperazine Maleate | 12 | $137 | $11 |
| Lorazepam | 18 | $70 | $4 |
| Omeprazole | 11 | $69 | $6 |
2019: 7 drugs
| Femara | 11 | $9,680 | $880 |
| Letrozole | 121 | $2,554 | $21 |
| Anastrozole | 42 | $946 | $23 |
| Ondansetron | 17 | $188 | $11 |
| Omeprazole | 13 | $156 | $12 |
| Prochlorperazine Maleate | 15 | $125 | $8 |
| Lorazepam | 15 | $55 | $4 |
2018: 6 drugs
| Enoxaparin | 27 | $2,665 | $99 |
| Letrozole | 137 | $2,639 | $19 |
| Anastrozole | 59 | $1,545 | $26 |
| Lamivudine Hbv | 12 | $1,355 | $113 |
| Alendronate | 16 | $197 | $12 |
| Lorazepam | 22 | $112 | $5 |
2017: 6 drugs
| Ibrance | 15 | $176,264 | $11,751 |
| Letrozole | 146 | $3,514 | $24 |
| Anastrozole | 63 | $803 | $13 |
| Alendronate | 18 | $134 | $7 |
| Lorazepam | 22 | $111 | $5 |
| Dexamethasone | 11 | $53 | $5 |
2016: 6 drugs
| Ibrance | 27 | $282,293 | $10,455 |
| Exemestane | 12 | $6,279 | $523 |
| Letrozole | 165 | $2,910 | $18 |
| Anastrozole | 70 | $1,004 | $14 |
| Tamoxifen Citrate | 11 | $252 | $23 |
| Alendronate | 12 | $38 | $3 |
2015: 5 drugs
| Ibrance | 20 | $197,523 | $9,876 |
| Exemestane | 15 | $5,157 | $344 |
| Letrozole | 129 | $1,711 | $13 |
| Anastrozole | 32 | $407 | $13 |
| Lorazepam | 11 | $80 | $7 |
2014: 5 drugs
| Exemestane | 20 | $5,179 | $259 |
| Anastrozole | 84 | $1,810 | $22 |
| Tamoxifen Citrate | 29 | $590 | $20 |
| Letrozole | 22 | $549 | $25 |
| Ondansetron | 12 | $291 | $24 |
2013: 4 drugs
| Anastrozole | 104 | $3,116 | $30 |
| Tamoxifen Citrate | 34 | $629 | $18 |
| Letrozole | 16 | $522 | $33 |
| Alendronate | 12 | $167 | $14 |
Money from drug and device companies
$7,094 in 2025
| 2025 | 4 | 11 | $6,211 | $7,094 |
| 2024 | 3 | 7 | $6,080 | $6,994 |
| 2023 | 2 | 3 | None | $273 |
| 2022 | 2 | 2 | $685 | $854 |
| 2021 | 2 | 3 | None | $30 |
| 2020 | 3 | 4 | $8,730 | $8,730 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | Itovebi | $5,515 | 5 payments
|
| Gilead Sciences | Trodelvy | $1,216 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $336 | 3 payments
|
| Merck Sharp & Dohme | Keytruda Qlex | $26 | 1 payment
|
See all 11 published payments
| Genentech USA | Consulting · 2025-12-08 | None | $2,731 |
| Genentech USA | Meals · 2025-12-08 | None | $157 |
| Merck Sharp & Dohme | Education · 2025-10-03 | Keytruda Qlex | $26 |
| Genentech USA | Meals · 2025-06-01 | None | $68 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-08 | None | $135 |
| Gilead Sciences | Consulting · 2025-04-04 | Trodelvy | $1,160 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-28 | None | $86 |
| Gilead Sciences | Meals · 2025-03-28 | Trodelvy | $56 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-06 | None | $115 |
| Genentech USA | Consulting · 2025-03-06 | Itovebi | $2,320 |
| Genentech USA | Meals · 2025-03-06 | Itovebi | $239 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $6,994
| Genentech USA | None | $6,639 | 3 payments
|
| Gilead Sciences | Trodelvy | $275 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | None | $79 | 1 payment
|
2023: $273
| Gilead Sciences | Trodelvy | $260 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $13 | 1 payment
|
2022: $854
| AstraZeneca Pharmaceuticals LP | Enhertu | $685 | 1 payment
|
| GE HealthCare | None | $169 | 1 payment
|
2021: $30
| Pfizer | Ibrance | $19 | 2 payments
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $8,730
| Seagen | Tukysa | $3,765 | 2 payments
|
| Genzyme | None | $3,090 | 1 payment
|
| Novartis Pharmaceuticals | Kisqali | $1,875 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · A Phase 1b2 Openlabel Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors · 2025 | Their institution | $1,157,127 |
| Amgen Inc. · A Phase 1 Study of Tvec in Combination With Paclitaxel, Nab-Paclitaxel, Or Endocrine Therapy in Patients With Breast Cancer and Other Solid Tumor Malignancies Who Have Evidence of Locally Injectable Disease · 2020 | Their institution | $989,960 |
| Amgen Inc. · A Phase 1 Study of Tvec in Combination With Paclitaxel, Nab-Paclitaxel, Or Endocrine Therapy in Patients With Breast Cancer and Other Solid Tumor Malignancies Who Have Evidence of Locally Injectable Disease · 2021 | Their institution | $829,381 |
| PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy A Arv471 in Combination With Abemaciclib · 2024 | Their institution | $782,398 |
| PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy B Arv471 in Combination With Ribociclib · 2024 | Their institution | $583,156 |
| Merck Sharp & Dohme Corporation · A Phase 1b Dose-Escalation Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of Myc Oncogene Overexpression · 2020 | Their institution | $567,680 |
| Regeneron Pharmaceuticals, Inc. · I-Spy 2 Trial (Investigation of Serial Studies To Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) · 2023 | Their institution | $388,199 |
| PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy B Arv471 in Combination With Ribociclib · 2025 | Their institution | $341,599 |
| AstraZeneca Pharmaceuticals LP · Capivasertib Plus Palbociclib Plus Fulvestrant for Hr/Her2 Advanced Breast Cancer Capitello 292. · 2025 | Their institution | $339,276 |
| PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy A Arv471 in Combination With Abemaciclib · 2025 | Their institution | $335,241 |
| Puma Biotechnology, Inc. · An Open?Label Study To Characterize the Incidence and Severity of Diarrhea · 2019 | Their institution | $331,640 |
| JAZZ PHARMACEUTICALS INC. · I-Spy Trial (Investigation of Serial Studies To Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) · 2025 | Their institution | $307,401 |
| Amgen Inc. · A Phase 1 Study of Tvec in Combination With Paclitaxel, Nab-Paclitaxel, Or Endocrine Therapy in Patients With Breast Cancer and Other Solid Tumor Malignancies Who Have Evidence of Locally Injectable Disease · 2022 | Their institution | $271,940 |
| PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy A Arv471 in Combination With Abemaciclib · 2023 | Their institution | $218,005 |
| PFIZER INC. · Ph 1b2 Dose Optimization Expansion Study of Disitamab Vedotin Monotherapy Or in Comb Wanticancer Therapies in Gastric Cancer Other Solid Tumors · 2024 | Their institution | $192,110 |
| Regeneron Pharmaceuticals, Inc. · I-Spy 2 Trial (Investigation of Serial Studies To Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) · 2024 | Their institution | $173,543 |
| Merck Sharp & Dohme Corporation · Ph II Study of Mk-3475 As Neo-Adjuvant Therapy in Tnbc · 2019 | Their institution | $165,321 |
| PUMA BIOTECHNOLOGY, INC. · Incidence and Severity of Diarrhea in Patients With Her2 Positive Breast Cancer Treated With Trastuzumab and Neratinib · 2023 | Their institution | $160,682 |
| Amgen Inc. · A Phase 1 Study of Tvec in Combination With Paclitaxel, Nab-Paclitaxel, Or Endocrine Therapy in Patients With Breast Cancer and Other Solid Tumor Malignancies Who Have Evidence of Locally Injectable Disease · 2023 | Their institution | $155,740 |
| PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy B Arv471 in Combination With Ribociclib · 2023 | Their institution | $142,277 |
| Merck Sharp & Dohme Corporation · Outcomes Trial for Keytruda-Neoadjuvant Therapy in Patients With High-Risk Breast Cancer. · 2020 | Their institution | $131,261 |
| PUMA BIOTECHNOLOGY, INC. · Project 10030/Ist 167514 An Open Label Study To Characterize the Incidence and Severity of Diarrhea in Patients With Early Stage Her2+ Breast Cancer Treated With Adjuvant Trastuzumab and Neratinib Followed By Neratinib Monotherapy, and Intensive Anti-Diar · 2021 | Their institution | $127,854 |
| Merck Sharp & Dohme Corporation · Ph II Study of Mk-3475 As Neo-Adjuvant Therapy in Tnbc · 2020 | Their institution | $122,482 |
| PUMA BIOTECHNOLOGY, INC. · An Open-Label Study To Characterize the Incidence and Severity of Diarrhea · 2020 | Their institution | $122,454 |
| Merck Sharp & Dohme Corporation · A Phase 1b Dose-Escalation Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of Myc Oncogene Overexpression · 2019 | Their institution | $119,755 |
| Seagen Inc. · A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced Or Metastatic Her2+ Breast Cancer · 2023 | Their institution | $118,635 |
| Merck Sharp & Dohme Corporation · A Phase 1b Dose-Escalation Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of Myc Oncogene Overexpression · 2021 | Their institution | $115,768 |
| PFIZER INC. · An Interventional Safety and Efficacy Phase 1b2 Openlabel Study To Investigate Tolerability Pk and Antitumor Activity of Vepdegestrant Arv471pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Pf07220060 in Participants Aged 18 Years and Older With Erher2 Advanced Or Metastatic Breast Cancer · 2025 | Their institution | $112,625 |
| Seagen Inc. · Study of Tucatinib Vs. Placebo in Combination With Ado-Trastuzumab Emtansine (T-Dm1) for Patients With Advanced Or Metastatic Her2+ Breast Cancer · 2021 | Their institution | $99,372 |
| PFIZER INC. · Patinaa Randomized Open Label Phase III Trial To Evaluate the Efficacy and Safety of Palbociclib Antiher2 Therapy Endocrine Therapy Vs Antiher2 Therapy Endocrine Therapy After Induction Treatment for Hrher2 Metastatic Breast Cancer · 2019 | Their institution | $75,955 |
| PFIZER INC. · A Single Arm Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locallyadvanced Or Metastatic Her2 Breast Cancer · 2025 | Their institution | $73,531 |
| Seattle Genetics, Inc. · Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib · 2019 | Their institution | $72,739 |
| Merck Sharp & Dohme Corporation · I-Spy 2 Trial Investigation of Serial Studies To Predict Your Therapeutic Response With Imaging and Molecular Analysis 2 · 2019 | Their institution | $68,001 |
| Seagen Inc. · A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced Or Metastatic Her2+ Breast Cancer · 2022 | Their institution | $63,450 |
| Regeneron Pharmaceuticals, Inc. · I-Spy 2 Trial (Investigation of Serial Studies To Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) · 2025 | Their institution | $51,450 |
| Seagen Inc. · Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib · 2020 | Their institution | $47,286 |
| PUMA BIOTECHNOLOGY, INC. · An Open-Label Study To Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage Her2+ Breast Cancer Treated With Neratinib and Loperamide · 2024 | Their institution | $46,000 |
| PFIZER INC. · A Phase 1b2 Openlabel Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors · 2024 | Their institution | $42,001 |
| Seagen Inc. · Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib · 2023 | Their institution | $40,776 |
| PFIZER INC. · An Interventional Safety and Efficacy Phase 1b2 Openlabel Study To Investigate Tolerability Pk and Antitumor Activity of Vepdegestrant Arv471pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Pf07220060 in Participants Aged 18 Years and Older With Erher2 Advanced Or Metastatic Breast Cancer · 2024 | Their institution | $40,336 |
| Seagen Inc. · Investigation of Serial Studies To Predict Your Therapeutic Response With Imaging and Molecular Analysis 2 - I-Spy2 · 2020 | Their institution | $38,334 |
| PUMA BIOTECHNOLOGY, INC. · A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (Hki-272) After Trastuzumab in Women With Early-Stage Her-2/Neu Overexpressed/Amplified Breast Cancer · 2020 | Their institution | $35,500 |
| PFIZER INC. · A Single Arm Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locallyadvanced Or Metastatic Her2 Breast Cancer · 2024 | Their institution | $32,745 |
| Seagen Inc. · Study of Tucatinib Vs. Placebo in Combination With Ado-Trastuzumab Emtansine (T-Dm1) for Patients With Advanced Or Metastatic Her2+ Breast Cancer · 2022 | Their institution | $32,673 |
| PFIZER INC. · Study of Tucatinib Vs Placebo in Combination With Adotrastuzumab Emtansine Tdm1 for Patients With Advanced Or Metastatic Her2 Breast Cancer · 2024 | Their institution | $27,976 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant As Treatment for Locally Advanced (Inoperable) Or Metastatic Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Following Recurrence Or Progression on Or After Treatment With An Aromatase Inhibitor (Capitello-291) · 2025 | Their institution | $26,612 |
| Seagen Inc. · Study of Tucatinib Vs. Placebo in Combination With Ado-Trastuzumab Emtansine (T-Dm1) for Patients With Advanced Or Metastatic Her2+ Breast Cancer · 2023 | Their institution | $25,789 |
| PFIZER INC. · Patinaa Randomized Open Label Phase III Trial To Evaluate the Efficacy and Safety of Palbociclib Antiher2 Therapy Endocrine Therapy Vs Antiher2 Therapy Endocrine Therapy After Induction Treatment for Hrher2 Metastatic Breast Cancer · 2020 | Their institution | $24,330 |
| PFIZER INC. · Randomized Doubleblind Phase 3 Study of Tucatinib Or Placebo in Combination With Adotrastuzumab Emtansine Tdm1 for Subjects With Unresectable Locallyadvanced Or Metastatic Her2 Breast Cancer Her2climb02 · 2024 | Their institution | $14,923 |
| PFIZER INC. · Patinaa Randomized Open Label Phase III Trial To Evaluate the Efficacy and Safety of Palbociclib Antiher2 Therapy Endocrine Therapy Vs Antiher2 Therapy Endocrine Therapy After Induction Treatment for Hrher2 Metastatic Breast Cancer · 2025 | Their institution | $13,300 |
| PFIZER INC. · The Compassher2 Trials Comprehensive Use of Pathologic Response Assessment To Optimize Therapy in Her2positive Breast Cancer Compassher2 Residual Disease Rd A Doubleblinded Phase III Randomized Trial of Tdm1 Compared With Tdm1 and Tucatinib · 2024 | Their institution | $10,000 |
| JAZZ PHARMACEUTICALS INC. · I-Spy Trial (Investigation of Serial Studies To Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) · 2024 | Their institution | $7,782 |
| Eli Lilly and Company · A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer · 2025 | Their institution | $5,361 |
| PFIZER INC. · Patinaa Randomized Open Label Phase III Trial To Evaluate the Efficacy and Safety of Palbociclib Antiher2 Therapy Endocrine Therapy Vs Antiher2 Therapy Endocrine Therapy After Induction Treatment for Hrher2 Metastatic Breast Cancer · 2021 | Their institution | $4,600 |
| PFIZER INC. · Ispy 2investigation of Serial Studies To Predict Your Therapeutic Response With Imaging and Molecular Analysis 2 · 2019 | Their institution | $3,450 |
| PFIZER INC. · Phase 2 Randomized Doubleblinded Controlled Study of Tucatinib · 2024 | Their institution | $3,000 |
| Seagen Inc. · Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib · 2021 | Their institution | $2,860 |
| Seagen Inc. · Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib · 2022 | Their institution | $1,560 |
| PFIZER INC. · Elranatamab Clinical Publication Program · 2025 | This clinician | $330 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1922242932
- Licence
- CA A95906California A95906: Current · expires 2027-12-31
- Trained
- Harvard Medical School, 2003 · 23 years ago
- Group
- University of California San Francisco · UCSF Medical Group Business Services
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 1600 Divisadero St, Helen Diller Comprehensive Cancer Center - UCSF, San Francisco, CA, 94143
- NPI first listed
- 2009-04-22
- NPI last updated
- 2009-04-22
This is when the NPI record was last certified, not a medical board exam.